Skip to content

Clinical Evaluation of Two Daily Disposable Lenses in Sphere Design

Clinical Evaluation of Two Daily Disposable Lenses in Sphere Design

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05516082
Enrollment
41
Registered
2022-08-25
Start date
2022-08-08
Completion date
2022-10-12
Last updated
2023-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ametropia

Brief summary

This was a single-blind, interventional, prospective, direct refit, bilateral wear, fixed-sequence crossover study.

Detailed description

The aim of this study was to evaluate the visual performance and subjective experiences of daily disposable hydrogel lens (DDH) when compared to daily disposable silicone hydrogel lens (DDSH) after 15 minutes of daily wear each.

Interventions

DEVICELens A

DDH contact lens for 15 minutes

DEVICELens B

DDSH contact lens for 15 minutes

Sponsors

CooperVision, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

All participants received Lens A and then Lens B in fixed-sequence order.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Is at least 18 years of age and has full legal capacity to volunteer. * Has read and signed an information consent letter. * Self-reports having a full eye examination in the previous two years. * Anticipates being able to wear the study lenses for the required time of the study. * Is willing and able to follow instructions and maintain the appointment schedule. * Has refractive astigmatism no higher than -0.75 DC. * Can be fit with the available lens parameters (sphere +8.00 to -10.00D). * Can achieve binocular distance vision of at least 20/30 Snellen (logMAR 0.18) with the study contact lenses.

Exclusion criteria

* Is participating in any concurrent clinical or research study. * Has any known active ocular disease and/or infection that contraindicates contact lens wear. * Has a systemic condition that in the opinion of the investigator may affect a study outcome variable. * Is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable. * Has known sensitivity to the diagnostic sodium fluorescein used in the study. * Self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment. * Has undergone refractive error surgery or intraocular surgery.

Design outcomes

Primary

MeasureTime frameDescription
Lens Fit Acceptance15 minutesMeasured on a scale of 0-4 (0 = Should not be worn, 1 = Borderline but unacceptable, 2 = Min. acceptable, early review, 3 = Not perfect but OK to dispense, 4 = Perfect) as assessed by an investigator.

Countries

Mexico

Participant flow

Participants by arm

ArmCount
All Study Participants
Includes all study participants.
41
Total41

Baseline characteristics

CharacteristicAll Study Participants
Age, Continuous28.6 years
STANDARD_DEVIATION 9.9
Race and Ethnicity Not Collected— Participants
Sex: Female, Male
Female
33 Participants
Sex: Female, Male
Male
8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 410 / 41
other
Total, other adverse events
0 / 410 / 41
serious
Total, serious adverse events
0 / 410 / 41

Outcome results

Primary

Lens Fit Acceptance

Measured on a scale of 0-4 (0 = Should not be worn, 1 = Borderline but unacceptable, 2 = Min. acceptable, early review, 3 = Not perfect but OK to dispense, 4 = Perfect) as assessed by an investigator.

Time frame: 15 minutes

Population: All participants wore Lens A and Lens B in sequential order.

ArmMeasureValue (MEAN)Dispersion
Lens ALens Fit Acceptance3.51 score on a scaleStandard Deviation 0.9
Lens BLens Fit Acceptance3.68 score on a scaleStandard Deviation 0.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026